|Day Low/High||0.30 / 0.37|
|52 Wk Low/High||0.32 / 1.99|
Vitaros® U.S. NDA Re-Submission on Schedule for 3Q 2016
Top-Line Phase 2b Data for Fispemifene Expected in Q1
Apricus Expects to Report Top-Line Phase 2b Data in Q1 2016
Apricus Eligible to Receive Up to $18.25 Million in Upfront and Milestone Payments, in Addition to Royalties on Net Sales
Apricus Reaffirms Plans to Move RayVa Into Late-Stage Clinical Trials in Patients With Scleroderma Who Also Suffer From Raynaud's Phenomenon
Apricus Biosciences (ARPI) shares are rising after it agreed to a license agreement with Allergan (AGN) for the U.S. rights to Vitaros.
Apricus to Lead Clinical and Regulatory Efforts; Allergan Retains Commercialization Option in U.S.
Vitaros Now Approved in Twenty-Two Countries in Europe Under the Decentralized Procedure